New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure

Annals of Pharmacotherapy

Volumn 35, Issue 1, 2001, Pages 71-84

  Martineau, P ^a   Goulet, J ^a  

^a PFIZER INC   (United States)

Author keywords

Angiotensin II receptor antagonists; Angiotensin converting enzyme inhibitors; Congestive heart failure

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; LOSARTAN;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONGESTIVE HEART FAILURE; COUGHING; DRUG TOLERABILITY; HEMODYNAMICS; HUMAN; HYPOTENSION; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL;

EID: 0035106503     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19307     Document Type: Review

References (109)

1. Le diagnostic et le traitement de l'insuffisance cardiaque
2. Natural history and patterns of current practice in heart failure
3. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management
4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
5. A comparison of enalapril with hydralazine - Isosorbide dinitrate in the treatment of chronic congestive heart failure
6. Effects of enalapril on mortality in severe congestive heart failure
7. Consensus recommendations for the management of chronic heart failure
8. Preventable causative factors leading to hospital admission with decompensated heart failure
9. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction
10. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure
11. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure?
12. Angiotensin-converting enzyme inhibitors in the management of cardiac failure: Are we ignoring the evidence?
13. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity, and mortality in chronic heart failure
14. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
15. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF)
16. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial
17. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
18. Pathophysiology of heart failure
19. Hormones and hemodynamics in heart failure
20. Activation of neurohumoral systems in postinfarction left ventricular dysfunction
21. The neurohumoral hypothesis and the treatment of heart failure
22. Plasma norepinephrine, plasma renin activity, and congestive heart failure
23. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
24. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure
25. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure
26. The chymase-angiotensin system in humans: Biochemistry, molecular biology and potential role in cardiovascular disease
27. The angiotensin II type 1 receptor antagonists: A new class of antihypertensive drugs
28. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm
29. Effect of angiotensin II blockade on cardiac hypertrophy and remodeling: A review
30. Functional effects of endogenous bradykinin in congestive heart failure
31. Acute effects of enalapril and losartan on fibrinolytic activity in cardiac failure
32. Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin system
33. Angiotensin II receptor subtypes and cardiac function
34. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors
35. Cardiac renin-angiotensin system: Role in development of pressure-overload hypertrophy
36. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis
37. Acute and long term effects of angiotensin type 1 receptor inhibition on endothelial dysfunction in atherosclerosis
38. Angiotensin receptors and their antagonists
39. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction
40. Recent insight into therapy of congestive heart failure: Focus on ACE inhibition and angiotensin II antagonism
41. Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension
42. Candesartan cilexetil: A review of its use in essential hypertension
43. Valsartan: A review of its pharmacology and therapeutic use in essential hypertension
44. Irbesartan: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension
45. Molecular biology of angiotensin II biosynthesis and receptors
46. Additive effect of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
47. Angiotensin II-forming pathways in normal and failing human hearts
48. Selective down-regulation of angiotensin II AT1 receptors in failing human heart: Relationship to beta I-receptor down-regulation
49. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type-1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors
50. Angiotensin II type 2 receptor mediates programmed cell death
51. Angiotensin induction of PA1-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
52. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin
53. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects
54. Biochemical effects of losartan, a non-peptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients
55. Losartan in heart failure; hemodynamic effects and tolerability
56. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
57. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil
58. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension
59. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects
60. Comparison of candesartan, enalapril, and their combination in congestive heart failure
61. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure
62. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study. ELITE)
63. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension
64. Blood pressure effects of the angiotensin II receptor blocker, losartan
65. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension
66. Clinical aspects of heart failure: High-output heart failure; pulmonary edema
67. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor inhibitor trials
68. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
69. Angiotensin II receptor antagonists in heart failure: Rationale and design of the Evaluation of Losartan in the Elderly (ELITE) trial
70. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure
71. Effects of vasodilator treatment on mortality in chronic congestive heart failure
72. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension
73. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure
74. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure
75. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: A double-blind, placebo-controlled study of quinapril
76. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: Results of the ELITE ventricular function substudy
77. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure
78. Effect of losartan compared with captopril on mortality, in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
79. Evaluation of losartan in the Elderly ELITE trial: Clinical implications
80. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A post-hoc analysis of the studies of left ventricular dysfunction
81. Mechanisms and models in heart failure; a combinatorial approach
82. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure
83. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure
84. 2 determination in chronic heart failure: Is it still of value?
85. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure
86. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure
87. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
88. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD pilot study)
89. Rationale, background, and design of the Randomized Angiotensin Receptor Antagonist-Angiotensin-Converting Enzyme Inhibitor Study (RAAS)
90. AT1-receptor blockers in hypertension and heart failure: Clinical experience and future directions
91. Efficacy and tolerability of losartan in hypertensive patients with renal impairment
92. ACE inhibitor-versus angiotensin II blocker-induced cough and angioedema
93. The angiotensin II receptor antagonist losartan: A new advance in the treatment of hypertension
94. Losartan in heart failure: Preclinical experiences and initial clinical outcomes
95. Angioedema induced by the angiotensin II blocker losartan
96. Accupril- and Cozaar-induced angioedema in the same patient
97. Angioedema associated with angiotensin II receptor antagonist losartan
98. Losartan-induced angioedema
99. Angioedema due to losartan
100. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
101. Hepatic injury associated with losartan
102. Marked hepatotoxicity associated with losartan treatment
103. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in health subjects
104. Hypotensive effect of losartan, a non-peptide angiotensin II receptor antagonist, in essential hypertension
105. The advantages of angiotensin II antagonism
106. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia
107. Toxicokinetic analysis of losartan during gestation and lactation in the rat
108. The pharmacokinetics of losartan in renal insufficiency